Pfizer's $13B New Product Push Aims to Blunt Eliquis Cliff by 2028

For biopharma analysts, the pivotal question is whether $13B in annualized new-product revenue can truly replace a best-seller like Eliquis before generics arrive in 2028. Bourla's claim that the coronavirus business is no longer distorting results is backed by 10 straight EPS beats, but the pipeline's durability under Medicare pricing pressure remains untested.

At a recent investor conference reported on September 20, 2026, Pfizer CEO Albert Bourla argued that the three forces that made the past few years so difficult for the pharmaceutical giant—tariffs and drug-pricing policies, declining COVID-19 product sales, and looming patent cliffs—are finally beginning to ease. The claim matters because Pfizer has become a battleground between income investors attracted to its ultra-high-yield dividend and skeptics who worry that Eliquis generics and fading pandemic revenue will erode the cash flows that support the payout.

“

For biopharma analysts, the pivotal question is whether $13B in annualized new-product revenue can truly replace a best-seller like Eliquis before generics arrive in 2028.

Bourla said Pfizer has addressed the first headwind by signing agreements with the U.S. government that grant tariff relief in exchange for selling certain medicines at reduced prices domestically. That is a notable shift because drug-pricing pressure has been a core overhang for large pharmaceutical companies. The company has also brought down its expense base by roughly $7.2 billion, improving its ability to convert revenue into earnings even as COVID product sales remain unimpressive. On the earnings front, Bourla pointed to striking consistency: over the past 10 quarterly reporting periods, Pfizer has exceeded Wall Street's EPS estimates in all 10 and beaten revenue expectations in nine. That suggests the COVID portfolio is no longer distorting results as much as it once did, though beat rates can reflect conservative guidance as much as operational strength.

To address patent cliffs, Pfizer has expanded its pipeline and product lineup through internal development and acquisitions. Bourla said these new or acquired products generate revenue at an annualized rate of $13 billion and are growing faster than the rest of the business. If sustained, that gives Pfizer a credible bridge toward the biggest remaining cliff: Eliquis. The anticoagulant has been a top-selling drug, and generics could enter the U.S. market by 2028. Even so, the revenue replacement math is not simple. New products may carry different margins, rebate structures, or therapeutic categories, and Medicare drug-pricing policies could compress returns.